Hybrigenics SA Logo

Hybrigenics SA

R&D provider of molecular interaction analysis to accelerate drug discovery for life science sectors.

ALHYG | PA

Overview

Corporate Details

ISIN(s):
FR0004153930
LEI:
9695003KQD0XMJYDX764
Country:
France
Address:
850 BOULEVARD SEBASTIEN BRANT, 67400 ILLKIRCH-GRAFFENSTADEN
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Hybrigenics Services is a specialized R&D solutions provider focused on the discovery and analysis of molecular interactions. With over 25 years of experience, the company offers a suite of proprietary platforms to support clients in the pharmaceutical, biotech, agroscience, and academic sectors. Its core offerings include the ULTImate Y2H™ system for comprehensive protein interaction screening, the YChemH platform for identifying drug-target interactions, and the Hybribody service for custom synthetic nanobody (VHH) selection and validation. Hybrigenics acts as a strategic partner, delivering high-quality, reliable data to accelerate early-stage drug discovery, elucidate mechanisms of action, and advance fundamental scientific research.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-04-30 18:00
Earnings Release
RÉSULTATS ANNUELS CONSOLIDÉS 2024
French 290.7 KB
2024-10-31 18:00
Earnings Release
RÉSULTATS SEMESTRIELS 2024
French 187.0 KB
2024-10-01 18:30
Post-Annual General Meeting Information
Assemblée générale mixte du 30 septembre 2024 : Approbation des comptes annuels…
French 272.4 KB
2024-07-18 18:00
Capital/Financing Update
ATON FINALISE AVEC SUCCES SA RESTRUCTURATION FINANCIERE
French 283.7 KB
2024-06-17 18:30
Pre-Annual General Meeting Information
ASSEMBLEE GENERALE ORDINAIRE LE 2 JUILLET 2024
French 142.5 KB
2024-06-07 18:30
Legal Proceedings Report
ENGAGEMENT DE DISCUSSIONS AVEC LES CREANCIERS EN VUE D'ASSAINIR LA SITUATION FI…
French 148.9 KB
2024-04-30 18:30
Earnings Release
RÉSULTATS ANNUELS 2023 - REPORT DE LA PUBLICATION DU RAPPORT ANNUEL 2023
French 248.9 KB
2024-03-07 18:00
Capital/Financing Update
ÉCHELONNEMENT DU REMBOURSEMENT DE L'EMPRUNT OBLIGATAIRE CONVERTIBLE DE 1,5 M EU…
French 240.5 KB
2024-02-22 18:00
Management Discussion and Analysis
2023 : une année de profondes transformations - Situation de trésorerie au 31 d…
French 282.3 KB
2023-12-22 18:00
Post-Annual General Meeting Information
Compte-rendu de l'assemblée générale du 21 décembre 2023
French 185.9 KB
2023-11-17 18:30
Business and Financial Review
POINT SUR LA SITUATION DU GROUPE ATON (HYBRIGENICS SA)
French 255.7 KB
2023-10-31 18:00
Earnings Release
RESULTATS SEMESTRIELS 2023
French 269.4 KB
2023-10-25 18:00
Capital/Financing Update
ATON (EX-HYBRIGENICS) RENFORCE SES RESSOURCES FINANCIERES EN EMETTANT UN EMPRUN…
French 297.2 KB
2023-10-11 08:00
Regulatory News Service
HYBRIGENICS : Stemcis étend ses horizons à l'international avec l'ouverture d'u…
French 183.5 KB
2023-09-26 17:45
Report Publication Announcement
HYBRIGENICS SE REPOSITIONNE SOUS LE NOM D'ATON ET COMMUNIQUE SA STRATÉGIE POUR …
French 1.4 MB

Automate Your Workflow. Get a real-time feed of all Hybrigenics SA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Hybrigenics SA

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Hybrigenics SA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Resolute Holdings Management, Inc. Logo
Asset management firm acquiring and operationally enhancing companies for long-term growth.
United States of America
RHLD
Develops RNA aptamer therapeutics for ophthalmology, pain, fibrosis, and other unmet medical needs.
Japan
4591
Rise Consulting Group, Inc. Logo
Execution-focused consulting for strategy and digital transformation, specializing in JP-CN markets.
Japan
9168
ROQUEFORT THERAPEUTICS PLC Logo
Developing first-in-class, pre-clinical medicines for hard-to-treat cancers.
United Kingdom
ROQ
ROSS GROUP PLC Logo
A holding company in liquidation, formerly providing supply chain management & technology solutions.
United Kingdom
RGP
ROXX, Inc. Logo
HR tech platform connecting non-desk job seekers with full-time roles using AI and vetting tools.
Japan
241A
SAFTEC CO.,LTD. Logo
Rents and sells safety equipment for construction, from basic supplies to AI/IoT solutions.
Japan
7464
Salarius Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing targeted protein therapies for cancer and viral diseases.
United States of America
SLRX
Saniona Logo
Develops ion channel medicines for rare neurological diseases and epilepsy.
Denmark
SANION
Santech Holdings Ltd Logo
A technology company developing innovative consumer and enterprise technology businesses.
United States of America
STEC

Talk to a Data Expert

Have a question? We'll get back to you promptly.